Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
Antimicrobial resistance is projected to kill up to 10 million people a year by 2050. One particular area of concern is drug-resistant gonorrhea, where existing therapies are being exhausted. Taxis Pharmaceuticals is developing therapies to combat evolving superbugs by targeting their cellular infrastructure and disrupting the mechanisms that fuel antimicrobial resistance. We spoke to Greg Mario, president and CEO of Taxis, about the public health threat posed by drug-resistant gonorrhea, the approaches it’s taking to develop new antimicrobial treatments, and the need for new funding models to bring new therapies to market.
No links were found in this episode’s notes.